Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer

NCT04508140 is registered in ClinicalTrials.gov with Highlight Therapeutics as lead sponsor.

NCT NCT04508140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Lead sponsor
Highlight Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
June 17, 2020
Completion date
December 2, 2022
Enrollment
18 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, oesophageal cancer